Four clinical-stage biotechs filed prospectus supplements to sell equity across a two-day window bridging June 30 and July 1, 2026, and taken together they read less like four company stories than like one capital-markets moment. Nuvectis Pharma, Abivax, Neurogene and Biodexa each filed a Form 424B5 dated June 30 to tap the public market — underwritten common-stock sales, American Depositary Share offerings, pre-funded-warrant structures and a warrant inducement. What ties them is not a therapeutic area but a decision: with equity available, each chose to raise it now and add cash rather than run down the balance sheet. The structures differ, and the dilution each creates differs with them.

The cleanest of the four to read, because it priced with hard numbers on the cover, is Nuvectis Pharma's. Per its 424B5, Nuvectis is selling 5,000,000 shares of common stock in an underwritten offering at a public offering price of $20.00 per share — $100,000,000 in gross proceeds. After a $1.40-per-share underwriting discount, or $7,000,000 in the aggregate, proceeds to the company before expenses come to $18.60 per share. The filing states the net figure directly:

We estimate that the net proceeds from our issuance and sale of 5,000,000 shares of our common stock in this offering will be approximately $93 million, after deducting underwriting discounts and commissions.— Nuvectis Pharma, Inc., Form 424B5 (SEC), source

Two structural details in the Nuvectis cover matter for anyone doing the dilution and runway math. First, the price. The stock's last reported sale on June 29, 2026 was $28.53 on the Nasdaq Capital Market; the $20.00 offering price is struck below that mark, the discount an underwritten deal typically needs to clear new supply. Second, the overhang. Nuvectis granted the underwriters a 30-day option to buy up to an additional 750,000 shares at the offering price less the discount; if exercised in full, the filing puts net proceeds at roughly $107 million and total underwriting discounts at about $8.1 million. Cantor is named sole bookrunner, and delivery of the shares was expected on or about July 1, 2026. The company says it will use the proceeds to advance its NXP100, NXP200 and NXP900 development programs, to hire personnel, for capital expenditures and for general corporate purposes — the standard clinical-stage runway-extension list, disclosed as intended use rather than committed spend.

Same window, four different structures

The other three filings show how varied the plumbing of a clinical-stage raise can be inside the same two days. Abivax filed a 424B5 to sell American Depositary Shares — each representing one ordinary share, €0.01 nominal value — in an underwritten public offering, drawn down off an automatic shelf registration statement the company had on file. The Abivax prospectus supplement is a preliminary one, with the share count, offering price and net-proceeds figures left blank to be filled at pricing; the cover notes that on June 29, 2026 the last reported sale price was €83.30 per ordinary share on Euronext Paris and $96.15 per ADS on Nasdaq. The mechanics there are worth flagging: an automatic shelf lets a well-known seasoned issuer take equity to market on short notice, and a dual-listed ADS structure prices against both the Paris and Nasdaq quotes. It is the optionality end of the spectrum — a shelf drawn down at management's timing.

Neurogene's 424B5 pairs common stock with pre-funded warrants — a structure that lets investors who would otherwise cross a beneficial-ownership threshold take warrants instead of shares, with an exercise price a fraction of a cent. Like Abivax's, the Neurogene supplement is preliminary, with price and proceeds blank pending the pricing, and its underwriting table carries the same placeholders. The cover reports a last sale price of $32.28 per share on the Nasdaq Global Market on June 29, 2026, and directs proceeds to general corporate purposes. Pre-funded warrants do not eliminate dilution; they defer the moment shares hit the count, and they let large holders participate without tripping the 4.99%/9.99% ownership caps that recur across these deals.

Biodexa's raise is the smallest and the most intricate. Per its 424B5, the company is offering 82,809 registered American Depositary Shares at a purchase price of $2.85 each — with each Depositary Share representing 500,000 ordinary shares of £0.000001 nominal value — plus 200,143 pre-funded warrants at $2.8499 for investors who would otherwise exceed the 4.99% (or elective 9.99%) ownership ceiling. The filing also describes a concurrent warrant inducement expected to yield gross proceeds of approximately $1.74 million before placement-agent fees and expenses. That is a micro-cap capital structure in miniature: a registered depositary-share tranche, a pre-funded-warrant tranche, and a separate inducement to get existing warrant holders to exercise, all stacked to pull a modest sum of cash into the business.

What the pattern discloses — and what it doesn't

Set side by side, the four filings map the toolkit clinical-stage issuers reach for when they add cash. At one end sits Nuvectis's fixed-price underwritten block, priced below the last trade and cleared through a single bookrunner in a day. Next to it, Abivax's automatic-shelf ADS takedown trades certainty of size for speed and timing flexibility. Neurogene's common-stock-plus-warrant structure and Biodexa's depositary-share-and-inducement stack both use pre-funded warrants to let concentrated buyers participate without breaching ownership caps. Every one of these mechanisms has the same first-order effect on holders — more shares, or the future right to them, against the same asset base — and each filing's own use-of-proceeds language frames the cash as runway for development programs and general corporate purposes, disclosed as intent, not guarantee.

The disciplined read stops at what the documents say. A 424B5 discloses structure, price where set, and stated use of proceeds; it does not disclose how many quarters of runway the cash buys, which depends on a burn rate these cover pages do not carry, or whether a program advances. Three of the four supplements — Abivax, Neurogene and the pricing-dependent lines throughout — were still preliminary when filed, meaning the definitive share counts and dollar figures print only at pricing. What the window does show, unambiguously, is timing: four clinical-stage names, four prospectus supplements dated the same June 30, four different equity structures, one shared choice to raise into an open market. The dilution is disclosed in each cover's mechanics; the runway it buys is left for the reader, and the next 10-Q, to compute.